)
Edge17 Oct 2025
A Castle in the Sky: The Story of Oracle
Oracle's journey from database innovator to disciplined enterprise backbone, now shaping the AI buildout with a standardized cloud infrastructure.
Cosmo Pharmaceuticals (COPN) investor relations material
Cosmo Pharmaceuticals H1 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H1 2025 earnings summary23 Jul, 2025
Executive summary
H1 2025 revenues reached €51.7 million, with EBITDA at €4.9 million and cash holdings of €133.3 million; recurring revenues remained stable while project-based revenues declined sharply due to a prior year milestone.
Strategic focus on execution, clinical pipeline advancement, and AI-driven medtech expansion, with major milestones including new product launches, regulatory progress, and global expansion in dermatology and AI platforms.
ESG initiatives advanced, with upgraded MSCI and LSEG ratings, improved peer ranking, and integration into operations.
Sale of digital trust assets and brand evolution sharpened focus and positioned for scalable growth.
Key pipeline progress includes solid tumor, bile acid diarrhoea, ulcerative colitis, and hair loss clinical trials advancing as planned.
Financial highlights
H1 2025 revenues were €51.7 million, down 62% year-over-year due to a €92.5 million Medtronic milestone in H1 2024; recurring revenues were €41.9 million, down 1% year-over-year; project-based revenues were €9.8 million, down 90%.
EBITDA for H1 2025 was €4.9 million, a 94% decrease from H1 2024; operating loss was €1.4 million versus €78.7 million profit in H1 2024.
Cash, equivalents, and investments totaled €133.3 million at June 30, 2025, down from €170.4 million at year-end 2024, with no significant new debt.
GI Genius recurring revenues grew 128% year-over-year to €8.7 million; Winlevi up 23% to €7.4 million; Gastro, CDMO & Other down 21%.
Operating expenses were €57.8 million; R&D declined due to planned wind-down, with increases expected in H2.
Outlook and guidance
Full-year 2025 revenue guidance set at €102–107 million, with recurring revenues of €85–90 million.
EBITDA guidance raised by €4.5 million to €5.5–7.5 million for the year, driven by cost control and first-half events.
Cash and investments expected to exceed €110 million at year-end.
H2 2025 expected to deliver double-digit revenue growth, EMA decision on Winlevi, and key clinical readouts.
What's driving Rifamycin's revenue growth?
Explain the rationale for Vision 2030.
Assess Al regulation impact on operations.
Solid tumor asset: partner or retain?
GI Genius: drivers for 2030 revenue ambition?
Winlevi EMA: confidence level change?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Cosmo Pharmaceuticals earnings date
H2 20255 Mar, 2026
Next Cosmo Pharmaceuticals earnings date
H2 20255 Mar, 2026
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Company Research17 Oct 2025
Beneath the Surface: A Conversation with Epiroc CEO Helena Hedblom
Legacy, innovation, and leading one of Sweden's most influential industrial companies into a new era.
)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Frequently asked questions
Cosmo Pharmaceuticals N.V. is a specialty pharmaceutical company focused on therapies for gastrointestinal diseases and medical devices for endoscopy procedures. The company engages in research, development, manufacturing, and commercialization of drug products and diagnostics. It serves both prescription drug and medical technology markets. The company is headquartered in Dublin, Ireland, and its shares are listed on the SIX.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage